Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti(University of Oxford), Alexander Batten, Maheshi Ramasamy(University of Oxford), Mustapha Bittaye(University of Oxford), Brian Angus(University of Oxford), Rachel Anslow, Edward H. Arbe-Barnes, Philip Baker, Paul T. Heath(St George's, University of London), K. F. Adams, Duncan Bellamy(University of Oxford), Jordan R. Barrett(National Institute for Health and Care Research), Eleanor Barnes(Oxford Health NHS Foundation Trust), Richard Tarrant(University of Oxford), J. Kenneth Baillie(NHS Lothian), Matthew D. Snape(University of Oxford), Elizabeth Clutterbuck(University of Oxford), Katie Ewer(University of Oxford), Adam Finn(University of Bristol), Adrian V. S. Hill(Jenner Institute), Parvinder K. Aley(University of Oxford), Christina Dold(University of Oxford), Catherine Green(University of Oxford), Daniel Jenkin(University of Oxford), Rebecca Makinson(University of Oxford), Sarah C. Gilbert(Nuffield Orthopaedic Centre), Angela M. Minassian(National Institute for Health and Care Research), Louise Bates, Gavin Babbage, Alexander D. Douglas(University of Oxford), Andrew J. Pollard(University of Oxford), Sagida Bibi(University of Oxford), Natalie Baker, Saul N. Faust(University Hospital Southampton NHS Foundation Trust), Ioana Baleanu, Elizabeth Allen, Sandra Belij‐Rammerstorfer(University of Oxford), Katrina M. Pollock(NIHR Imperial Biomedical Research Centre), Bassam Hallis(Public Health England), Amy Flaxman(University of Oxford), Merryn Voysey(Stratasys (Israel)), Juliana Ballaminut, Hannah Robinson(University of Oxford), Stephan Becker(Philipps University of Marburg), Jeremy Aboagye, Aabidah Ali, Jennifer L. Allison, Teresa Lambe(Science Oxford), Megan Baker, Rajeka Lazarus(University Hospitals Bristol NHS Foundation Trust)
The Lancet
July 20, 2020
Cited by 2,614


Related Papers